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In melanoma, the RAS/RAF/MEK/ERK signalling pathway is an area of great interest, because it regulates tumor cell
proliferation and survival. A varying mutation rate has been reported for B-RAF and N-RAS, which has been largely attributed
to the differential source of tumor DNA analyzed, e.g., fixed tumor tissues or in vitro propagated melanoma cells. Notably, this
variation also interfered with interpreting the impact of these mutations on the clinical course of the disease. Consequently,
we investigated the mutational profile of B-RAF and N-RAS in biopsies and corresponding cell lines from metastatic tumor
lesions of 109 melanoma patients (AJCC stage III/IV), and its respective impact on survival. 97 tissue biopsies and 105 biopsy-
derived cell lines were screened for B-RAF and N-RAS mutations by PCR single strand conformation polymorphism and DNA
sequencing. Mutations were correlated with patient survival data obtained within a median follow-up time of 31 months. B-
RAF mutations were detected in 55% tissues and 51% cell lines, N-RAS mutations in 23% tissues and 25% cell lines,
respectively. There was strong concordance between the mutational status of tissues and corresponding cell lines, showing
a differing status for B-RAF in only 5% and N-RAS in only 6%, respectively. Patients with tumors carrying mutated B-RAF
showed an impaired median survival (8.0 versus 11.8 months, p=0.055, tissues; 7.1 versus 9.3 months, p=0.068, cell lines),
whereas patients with N-RAS-mutated tumors presented with a favorable prognosis (median survival 12.5 versus 7.9 months,
p=0.084, tissues; 15.4 versus 6.8 months, p=0.0008, cell lines), each in comparison with wildtype gene status. Multivariate
analysis qualified N-RAS (p=0.006) but not B-RAF mutation status as an independent prognostic factor of overall survival. Our
findings demonstrate that B-RAF and N-RAS mutations are well preserved during short term in vitro propagation and, most
importantly, differentially impact the outcome of melanoma patients.
Citation: Ugurel S, Thirumaran RK, Bloethner S, Gast A, Sucker A, et al (2007) B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro
Propagation and Differentially Impact Prognosis. PLoS ONE 2(2): e236. doi:10.1371/journal.pone.0000236
INTRODUCTION
Malignant melanoma is associated with genetic heterogeneity and
a complex etiology. In contrast to other skin cancers, melanoma
affects a younger population and has a strong tendency to
metastasize with a consequently extremely poor overall survival. In
the majority of melanomas, the RAS/RAF/MEK/ERK signalling
pathway is constitutively activated either due to oncogenic
mutations in B-RAF and N-RAS genes or through autocrine
growth factor stimulation [1]. RAS proteins are membrane-bound
small G proteins, whereas RAF, MEK, and ERK are cytosolic
protein kinases that form a tiered protein kinase cascade
downstream of RAS. Signalling is initiated, when active RAS
recruits RAF to the plasma membrane for activation through
a complex process requiring lipid and protein binding, conforma-
tional changes, and regulatory phosphorylation and dephosphor-
ylation events. There are three RAF proteins in mammals, A-
RAF, B-RAF, and C-RAF, which can all activate MEK, but
clearly perform distinct functions in vivo as shown by the
phenotypic differences between A-RAF, B-RAF, and C-RAF
knock-out mice.
It has long been known that activating N-RAS codon 61
mutations occur in up to 30% of all cutaneous melanoma cases. In
2002, Davies et al. reported that B-RAF mutations occur at a high
frequency in melanoma; mutations were found in 20 of 34
melanoma cell lines (59%), 12 of 15 short-term cultures (80%), and
six of nine melanoma tumours (67%) [2]. Mutations in the B-RAF
gene are mainly localized in the kinase activation domain with the
majority involving the substitution of valine by acidic or basic
residues at codon 600 [2,3]. This mutation results in a strong
activation of B-RAF, constitutively stimulating the MEK-ERK
signaling pathway. In contrast, A-RAF and C-RAF have not been
found to be mutated because their regulation is fundamentally
different from that of B-RAF. The report by Davies et al.
stimulated a large research effort, which confirmed the originally
reported high frequency of B-RAF mutations in melanoma.
However, this frequency ranges between 30% to 70%, a variation,
that has been largely attributed to the differential source of the
analysed tumor DNA, e.g. fixed tumor tissues or in vitro
propagated melanoma cells. Notably, the variation also interfered
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PLoS ONE | www.plosone.org 1 February 2007 | Issue 2 | e236with the conclusive interpretation of the impact of these mutations
on the clinical course of the disease.
The observation that mutations in B-RAF and N-RAS are
mutually exclusive lead to the hypothesis, that the activation of
either B-RAF or N-RAS results in a similar cellular phenotype
[3,4,5,6,7]. However, recent reports about the association of B-
RAF and/or N-RAS mutations with the prognosis of melanoma
patients revealed contradictory results [5,7,8,9,10], requiring
clarification by further studies, particularly given the varying
frequencies of the reported B-RAF and N-RAS mutations. The
present study is the first to investigate the mutational profile of B-
RAF and N-RAS in both, tumor tissue biopsies and correspond-
ing, biopsy-derived cell lines from metastatic melanoma patients,
in correlation with a putative impact on survival. The analysis
included 97 tumor tissues and 105 cell lines from 109 melanoma
patients with a median follow-up time of 31 months. The study is
reported following the newly established REMARK guidelines
[11].
METHODS
Patients
Patients were enrolled in accordance with the following eligibility
criteria: histologically confirmed melanoma of the skin, mucosa, or
unknown primary; stage III or IV disease according to AJCC [12];
and at least one metastatic lesion accessible for a bioptic
procedure. Patient inclusion was allowed with or without current
systemic treatment. Patients with primary ocular melanomas were
excluded. After a patient’s written informed consent, one biopsy
was obtained from either a solid metastatic lesions or a malignant
effusion. Biopsies from solid lesions were subsequently divided into
three parts: one was immediately frozen down in liquid nitrogen
until further analysis, the second was used for histopathological
confirmation of melanoma, and the third was used for establishing
a permanently growing melanoma cell line. Patient charts were
reviewed for characteristics of the primary tumor (site and
histological type of primary). The patient’s age and disease stage
at the time of biopsy were recorded. Follow-up examinations were
performed at least once every three months. All tumor samples
and clinical data were collected with Institutional Review Board
approval and patient’s informed consent.
Tissues and cell lines
The frozen solid tumor tissue samples were used for DNA isolation
by RNase and proteinase K digestion and subsequent phenol-
chloroform extraction [13]. The biopsy-derived cell lines were
maintained in RPMI 1640 (Life Technologies, Grand Island, NY)
supplemented with 10% fetal calf serum (FCS; Life Technologies),
5 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml strepto-
mycin at 37uC in a humidified 5% CO2 atmosphere. They were
used for analysis not before six to eight culture passages. After
growing until 70 to 80% confluence, the cells were gently detached
using 0.05% ethylenediaminetetraacetic acid (EDTA)/phosphate-
buffered saline (PBS), washed twice, resuspended in 10% FCS/
RPMI and frozen down in liquid nitrogen. DNA was extracted
using the Puregene DNA purification kit (Gentra Systems,
Minneapolis, MN).
Mutation detection by single strand conformation
polymorphism (SSCP)
Fluorescent capillary SSCP technique was used to detect
mutations in exon 15 of the B-RAF gene and exon 2 of the N-
RAS gene. Briefly, the exons were amplified by PCR using
primers labeled with 6-FAM and HEX fluorescent dye (Applied
Biosystems, Foster City, CA) under conditions described earlier
[6,10]. The electrophoresis of the amplified products was carried
out under non-denaturing conditions in a 16-array capillary
sequencer (ABI3100; Applied Biosystems). Mutations were
detected by differential migration patterns compared to fragments
that contained wild type sequences. The analysis of the results was
carried out using the GeneScan software (Applied Biosystems). In
exon 11 of the B-RAF gene and in exon 1 of the N-RAS gene
mutations were screened by ‘radio-active’ SSCP technique. The
DNA fragments were amplified by PCR in presence of [a-
32P]
dCTP and the amplified products were electrophoresed on non-
denaturing MDE gels under different conditions as described
earlier [6,10].
Direct DNA sequencing
Direct DNA sequencing was used to identify and confirm
mutations detected in the B-RAF and N-RAS genes by SSCP.
For sequencing, PCR products were incubated with ExoSapIT
(USB Amersham, Uppsala, Sweden) at 37uC for 30 min followed
by heating to 85uC for 15 min. The sequencing reactions were
carried out using the BigDye Terminator Cyle sequencing kit
(Applied Biosystems) in a 10 ml volume containing purified PCR
product and a sequencing primer. The temperature conditions set
for sequencing reactions were 96
oC for 2 minutes followed by 27
cycles at 96uC for 30 seconds, 54uC for 10 seconds and 60uC for
4 minutes. The reaction products were precipitated with 2-
propanol, washed with 75% ethanol, resuspended in 25 ml water
and loaded onto ABI prism 3100 Genetic Analyzer (Applied
Biosystems). Both, forward and reverse strands were sequenced
separately. Primary sequencing data were analyzed using a se-
Table 1. Patient characteristics.
......................................................................
Patients enrolled 109 (100.0%)
Gender male 59 (54.1%)
female 50 (45.9%)
Age at biopsy (years) median (range) 56 (14–87)
Stage at biopsy (AJCC) III 27 (24.8%)
IV 82 (75.2%)
Site of primary skin 84 (77.1%)
mucosa 2 (1.8%)
occult 14 (12.8%)
n.a. 9 (8.3%)
Type of primary NM 30 (27.6%)
SSM 20 (18.3%)
ALM 7 (6.4%)
LMM 2 (1.8%)
mucosa 2 (1.8%)
amelanotic 2 (1.8%)
occult 14 (12.9%)
n.a. 32 (29.4%)
Patients were enrolled in accordance with the following eligibility criteria:
histologically confirmed melanoma of the skin, mucosa, or unknown primary;
stage III or IV disease; and at least one metastatic lesion accessible for a bioptic
procedure. AJCC, American Joint Committee on Cancer; NM, nodular
melanoma; SSM, superficial spreading melanoma; ALM, acrolentiginous
melanoma; LMM, lentigo maligna melanoma; occult, melanoma of unknown
primary; n.a., not available.
doi:10.1371/journal.pone.0000236.t001
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PLoS ONE | www.plosone.org 2 February 2007 | Issue 2 | e236quence analysis software (Sequence Analysis 3.7; Applied
Biosystems) and comparative analysis was done with the online
MultAlin software (http://www.prodes.toulouse.inra.fr/multalin/
multalin.html).
Statistics
Survival curves and median survival times were, if not otherwise
indicated, calculated from the date of biopsy until either death
from melanoma or last patient contact, respectively, and are
graphically presented using the Kaplan-Meier method for
censored failure time data. The log rank test was used for
comparing survival probabilities. The multivariate proportional
hazards regression of Cox was used to assess the impact of multiple
prognostic factors on survival. The factors tested were mutational
status of B-RAF and N-RAS, gender, disease stage at biopsy, and
site of primary tumor. Statistical analyses were performed using
the statistical packages ADAM (Central Unit for Biostatistics,
German Cancer Research Center Heidelberg, Germany) and SAS
8.1 (SAS Institute, Cary, NC). Differences with a p value ,0.05
were considered statistically significant.
RESULTS
109 metastatic melanoma patients were enrolled into the study
(Table 1); the patient flow is presented in Figure 1. The median
follow-up time was 31 months. Biopsies were obtained from 102
solid metastatic lesions and seven malignant effusions. The solid
lesions included 48% cutaneous or subcutaneous metastases, 45%
lymph node metastases, and 7% organ metastases (brain, liver,
lung, small bowel, urinary bladder and kidney). Routine
histopathology confirmed metastases from melanoma in all cases.
The malignant effusions originated from ascites (five patients) and
pleura (two patients). Permanently growing melanoma cell lines
could be established from 98 out of 102 solid lesions and from all
seven effusions. DNA of analysis grade could be isolated from 97
out of 102 tissue biopsies and from all 105 biopsy-derived cell lines,
and screened for mutations in exons 11 and 15 of the B-RAF gene
and exons 1 and 2 of the N-RAS gene. Detailed patient
characteristics as well as mutational profiles of tumor tissues and
cell lines are presented in Table 2. Representative data from
SSCP analysis and DNA sequencing are shown in Figure 2.
Mutations in B-RAF and N-RAS genes
Screening of exons 11 and 15 of the B-RAF gene resulted in the
detection of mutations in 53/97 (54.6%) tissue biopsies and 53/
105 (50.5%) biopsy-derived cell lines (Tables 2 and 3). The most
common mutation in the B-RAF gene was T1799A detected in
46/105 (43.7%) cell lines and 47/97 (48.5%) tissue biopsies. This
mutation causes a change from valine to glutamic acid at codon
600 in exon 15 (V600E). Five cell lines carried the GT1798-99AA
mutation at codon 600 (V600K). The only non-600 codon
mutation in exon 15 was G1780A (D594N), found in one single
cell line (Ma-Mel-30). All of the B-RAF mutations in exon 15 were
Figure 1. Schematic presentation of the study flow.
doi:10.1371/journal.pone.0000236.g001
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PLoS ONE | www.plosone.org 6 February 2007 | Issue 2 | e236concordant in cell lines and corresponding tissues except in five
cases: The cell line UKRV-Mel-29 but not the corresponding
tissue sample carried the V600K mutation, whereas the corre-
sponding tissue biopsies but not the cell lines UKRV-Mel-11, Ma-
Mel-104, Ma-Mel-113 and Ma-Mel-121a carried the V600E
mutation. In exon 11 of the B-RAF gene we detected two
mutations, G469R and G469V. The first was found in the cell line
Ma-Mel-48a and its corresponding tissue, whereas the latter was
present in a tissue biopsy with no corresponding cell line available.
Mutations in the N-RAS gene mostly occurred at codon 61 of
exon 2 and were present in 19/97 (19.6%) tissue biopsies and 22/
105 (21.0%) biopsy-derived cell lines (Tables 2 and 3). The cell
line Ma-Mel-53 and its corresponding tissue in addition to the
codon 61 mutation carried a second N-RAS mutation at codon 68
(R68T). Four cell lines (Ma-Mel-31, Ma-Mel-37b, Ma-Mel-79b
and Ma-Mel-53) revealed mutations in exon 2 (Q61R, Q61L,
Q61K and R68T, respectively) that could not be detected in the
corresponding tissue biopsies. One mutation (Q61R) detected in
a tumor tissue was not present in the corresponding cell line Ma-
Mel-02. Mutations in exon 1 at codon 12 and 13 of the N-RAS
gene were detected in four cell lines and three corresponding tissue
samples, respectively. The mutation G12D in the cell line Ma-
Mel-27 could not be detected in the matching tissue biopsy.
Taken together, 73/97 (75.3%) tumor tissue biopsies and 77/
105 (73.3%) biopsy-derived cell lines carried mutually exclusive
mutations in B-RAF or N-RAS (Table 3). Only one cell line (Ma-
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Table 3. Overview on B-RAF and N-RAS mutation status.
......................................................................
Tissues Cell lines
97 (100.0%) 105 (100.0%)
B-RAF mutation 53 (54.6%) 53 (50.5%)
Exon 11 2 (2.0%) 1 (1.0%)
G469R 1 (1.0%) 1 (1.0%)
G469V 1 (1.0%) 0 (0.0%)
Exon 15 51 (52.6%) 52 (49.5%)
D594N 1 (1.0%) 1 (1.0%)
V600E 47 (48.5%) 46 (43.7%)
V600K 3 (3.1%) 5 (4.8%)
N-RAS mutation 22 (22.7%) 26 (24.8%)
Exon 1 3 (3.1%) 4 (3.8%)
G12D 1 (1.0%) 2 (1.8%)
G13D 1 (1.0%) 1 (1.0%)
G13R 1 (1.0%) 1 (1.0%)
Exon 2 19 (19.6%) 22 (21.0%)
Q61R 11 (11.3%) 12 (11.4%)
Q61L 1 (.0%) 2 (1.8%)
Q61K 6 (6.3%) 8 (7.8%)
Q61H 1 (1.0%) 0 (0.0%)
R68T 0 (.0%) 1* (1.0%)
B-RAF or N-RAS mutation 73 (75.3%) 77 (73.3%)
B-RAF and N-RAS mutation 1 (1.0%) 1 (1.0%)
No B-RAF or N-RAS mutation 23 (23.7%) 27 (25.7%)
Tumor tissue biopsies and biopsy-derived cell lines from 109 metastatic
melanoma patients were analysed for B-RAF and N-RAS mutations. For details
see Figure 1 and Table 2. *This cell line additionally carries the N-RAS Q61K
mutation.
doi:10.1371/journal.pone.0000236.t003
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B-RAF and N-RAS in Melanoma
PLoS ONE | www.plosone.org 7 February 2007 | Issue 2 | e236Mel-30) and corresponding tissue carried mutations in both, B-
RAF (D594N) and N-RAS (G13D) genes.
Differential impact of B-RAF and N-RAS mutations
on survival
During a median follow-up time of 31.0 months, 80 (73.4%) out of
109 patients died from melanoma. Patients whose tumor tissue
biopsies revealed a mutation in the B-RAF gene showed
a decreased probability of overall survival from date of biopsy
compared to patients without a B-RAF mutation (median 8.0
versus 11.8 months, p=0.055; Figure 3A). This correlation of
borderline significance could similarly be detected in patients,
from whose tumor biopsies permanently growing cell lines could
be established (B-RAF mutation compared to wildtype, median
overall survival 7.1 versus 9.3 months, p=0.068; Figure 3D).
Patients carrying an N-RAS mutation in their tumor tissue
biopsies revealed an improved survival compared to patients
without an N-RAS mutation (median 12.5 versus 7.9 months,
p=0.084; Figure 3B). This association could be detected to
a stronger extent in patients whose biopsy-derived tumor cell lines
carried an N-RAS mutation compared to those patients without
such mutation (median overall survival 15.4 versus 6.8 months,
p=0.0008; Figure 3E). Looking at a subgroup of 82 patients who
were in stage IV at the time of tumor biopsy, again patients
harbouring a B-RAF mutation showed a reduced overall survival
compared to patients with wildtype B-RAF (p=0.043, tissues,
Figure 4A; p=0.091, cell lines, Figure 4D), whereas patients
holding an N-RAS mutation presented a favorable survival
compared to patients without N-RAS mutation (p=0.052, tissues,
Figure 4B; p=0.001, cell lines, Figure 4E).
With regard to overall survival measured from first diagnosis of
melanoma, no significant differences were seen by B-RAF or N-
RAS mutation status, respectively, neither for patients whose
mutation status was determined from tissue specimens, nor for
those, whose mutation status was measured in cell lines (data not
shown). Calculating overall survival starting with the first diagnosis
of metastasis, patients carrying a B-RAF mutation revealed a trend
to a decreased survival compared to patients with wildtype B-RAF
(p=0.052, tissues; p=0.072, cell lines), whereas patients carrying
Figure 2. Detection and identification of B-RAF and N-RAS mutations in melanoma cell lines and corresponding tissues by fluorescent capillary
electrophoresis SSCP and DNA sequencing. Migration patterns under non-denaturing conditions of single stranded fragments of exon 15 of the B-
RAF gene with a T1799A mutation at codon 600 in the cell line Ma-Mel-36 (A) and the corresponding tumor tissue (B). Migration patterns for the B-
RAF exon 15 fragments with wild type sequences in the cell line Ma-Mel-37a (C) and the corresponding tumor tissue (D). Panels (E) to (H) show
sequence analyses of the cell lines and tumor tissues given in (A) to (D). Fluorescent capillary electrophoresis patterns for the N-RAS exon 2 sequence
with a CAA.CGA mutation at codon 61 in the cell line Ma-Mel-05 (I) and the corresponding tumor tissue (J). Migration patterns for the N-RAS exon 2
fragments with wild-type sequences in the cell line Ma-Mel-59 (K) and the corresponding tumor tissue (L). Panels (M) to (P) show the confirmation of
the mutations in the cell lines and tissues shown in (I) to (L) by sequence analysis.
doi:10.1371/journal.pone.0000236.g002
B-RAF and N-RAS in Melanoma
PLoS ONE | www.plosone.org 8 February 2007 | Issue 2 | e236Figure 3. Kaplan-Meier survival estimation for the whole patient population by mutational status. Curves showing the overall survival of 109
metastatic melanoma patients starting from the time point of tumor biopsy. Survival probabilities were compared by the mutational status of B-RAF
in tumor tissue biopsies (n=97) (A) and biopsy-derived tumor cell lines (n=105) (D), as well as N-RAS in tumor tissue biopsies (n=97) (B) and biopsy-
derived tumor cell lines (n=105) (E). (C) and (F) differentiate patients harbouring B-RAF mutations (n=52, tissues; n=52, cell lines), patients
harbouring N-RAS mutations (n=21, tissues; n=25; cell lines), and patients without mutations in both genes (n=24, tissues; n=27, cell lines).
Statistical differences between groups were calculated using the log-rank test. Vertical bars indicate censored observations.
doi:10.1371/journal.pone.0000236.g003
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PLoS ONE | www.plosone.org 9 February 2007 | Issue 2 | e236Figure 4. Kaplan-Meier survival estimation for stage IV patients only by mutational status. Curves showing the overall survival starting with the
time point of tumor biopsy in 82 metastatic melanoma patients who were in stage IV disease at that time. Survival probabilities were compared by
the mutational status of B-RAF in tumor tissue biopsies (n=70) (A) and biopsy-derived tumor cell lines (n=80) (D), as well as N-RAS in tumor tissue
biopsies (n=70) (B) and biopsy-derived tumor cell lines (n=80) (E). (C) and (F) differentiate patients harbouring B-RAF mutations (n=43, tissues;
n=45, cell lines), patients harbouring N-RAS mutations (n=12, tissues; n=15; cell lines), and patients without mutations in both genes (n=15,
tissues; n=20, cell lines). Statistical differences between groups were calculated using the log-rank test. Vertical bars indicate censored observations.
doi:10.1371/journal.pone.0000236.g004
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PLoS ONE | www.plosone.org 10 February 2007 | Issue 2 | e236an N-RAS mutation showed a trend towards a favorable survival
compared to patients without N-RAS mutation (p=0.18, tissues;
p=0.12, cell lines).
A multivariate analysis using the proportional hazards model of
Cox revealed the disease stage at biopsy as the only factor of
independent prognostic impact on overall survival from date of
biopsy with regard to tissue analysis (p=0.03; Table 4). B-RAF
and N-RAS mutation status both showed a p=0.19). Site of
primary (p=0.27), and gender (p=0.79) did not show major
influence on survival. The analysis of biopsy-derived tumor cell
lines revealed the N-RAS mutation status as the strongest
prognostic factor (p=0.006), followed by disease stage at biopsy
(p=0.02), site of primary (p=0.14), and B-RAF mutation status
(p=0.29). Similar data were obtained analysing the subgroup of
82 stage IV patients (Table 4). Additional analyses were
performed dividing the patients into three groups, (i) patients
harbouring B-RAF mutations, (ii) patients harbouring N-RAS
mutations, and (iii) patients without mutations in both genes.
These analyses revealed, that with regard to the entire patient
population (n=109), patients harbouring B-RAF mutations show
a similar survival as patients without a mutation in B-RAF or N-
RAS, whereas patients carrying an N-RAS mutation present with
a favorable survival (p=0.11, tissues, Figure 3C; p=0.004, cell
lines, Figure 3F). This finding could be similarly observed when
looking at the subgroup of 82 patients, whose tumor biopsy was
obtained during stage IV disease (p=0.087, tissues, Figure 4C;
p=0.003, cell lines, Figure 4F).
DISCUSSION
The strong concordance between the mutational status of tissues
and corresponding cell lines, showing a differing status for B-RAF
in only 5% and N-RAS in only 6%, respectively, strongly argues
Table 4. Multivariate survival analysis.
..................................................................................................................................................
all patients stage IV patients
Variable Hazard ratio 95% CI P Hazard ratio 95% CI P
Tissue biopsies
gender
male 1 0.4 to 1.9 0.79 1 0.5 to 1.7 0.87
female 0.9 1.0
site of primary
skin 1 0.5 to 2.2 0.27 1 0.4 to 2.4 0.99
other 1.1 1.0
stage at biopsy
III 1 1.3 to 4.9 0.03 n.a.
IV 2.0
B-RAF
wt 1 0.8 to 3.1 0.19 1 0.6 to 3.0 0.41
mutation 1.4 1.4
N-RAS
wt 1 0.3 to 1.1 0.19 1 0.2 to 1.7 0.34
mutation 0.6 0.6
Biopsy-derived cell lines
gender
male 1 0.4 to 2.0 0.75 1 0.6 to 1.8 0.91
female 0.9 1.0
site of primary
skin 1 0.6 to 2.5 0.14 1 0.7 to 2.9 0.30
other 1.2 1.4
stage at biopsy
III 1 1.4 to 4.2 0.02 n.a.
IV 2.3
B-RAF
wt 1 0.8 to 3.0 0.29 1 0.7 to 3.3 0.36
mutation 1.3 1.4
N-RAS
wt 1 0.1 to 0.8 0.006 1 0.1 to 0.6 0.002
mutation 0.4 0.3
The prognostic impact of multiple variables was analysed using the multivariate proportional hazards regression of Cox. Overall survival was calculated beginning with
the date of tumor biopsy. wt, wildtype; CI, confidence interval; n.a., not applicable.
doi:10.1371/journal.pone.0000236.t004
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PLoS ONE | www.plosone.org 11 February 2007 | Issue 2 | e236against the notion that in vitro short term propagation biases the
frequency of mutational events in genes encoding the MAPK
signaling pathway. The finding that these mutations are preserved
throughout in vitro tumor propagation suggests, that they may
influence tumor maintenance. In support of this idea, studies in
a mouse model system have shown, that activated RAS is required
for melanoma maintenance [14]. Moreover, our findings validate
earlier reports using short term propagated melanoma cell culture
for genotypic analysis.
Until recently, it has been anticipated that B-RAF and N-RAS
mutations result in an activation of the RAS/RAF/MEK/ERK
signalling pathway, thus in a comparable cellular phenotype which
would similarly influence the clinical outcome of melanoma
patients. Consequently, the majority of previous reports consid-
ered patients with mutations in B-RAF or N-RAS as one
prognostic group. In this regard, Houben et al. showed mutations
in B-RAF or N-RAS to be associated with an impaired overall
survival in patients with metastatic melanoma [5]. Similarly,
Daniotti et al. studied patient-derived melanoma cell lines and
found a correlation of mutations in either B-RAF or N-RAS with
poor overall survival [8]. However, Dumaz et al. demonstrated
that cAMP suppresses C-RAF activity in melanocytes, and that
this suppression is essential to decrease the oncogenic potential of
C-RAF in these cells [15]. As a result, B-RAF alone is responsible
for signaling to MEK. When N-RAS is mutated, though, cells
switch their signalling from B-RAF to C-RAF, i.e. a fundamental
switch in RAF isoform usage occurs when RAS is mutated in
melanoma. Indeed, in a recent study comparing gene expression
profiles of melanoma cell lines with either mutations in B-RAF or
N-RAS, we found twice as many upregulated genes in cell lines
carrying N-RAS mutations than in those carrying mutations in B-
RAF, with an overlap of only 16% [16]. Pathway analysis of the
affected genes suggested, that the major B-RAF mutation V600E
mainly affects the ERK signaling pathway, whereas mutations in
N-RAS cause perturbation of the expression in genes involved in
the PI3K/AKT apoptotic pathway.
These observations should have important implications for the
analysis of the prognostic relevance of B-RAF and N-RAS
mutations as well as the development of therapeutic strategies to
treat this life-threatening disease [17]. Many of the newly
developed targeted therapeutics are multikinase inhibitors, but
nevertheless exert affinities of different strength to different
kinases. Sorafenib (BAY 43-9006), a multikinase inhibitor recently
tested in metastatic melanoma with significant efficacy, has a much
stronger affinity to RAF compared with that to RAS, whereas
farnesyl transferase inhibitors interfere with the translocation of
RAS but not RAF to the cell membrane. With regard to this issue,
we distinguished between B-RAF and N-RAS mutations in regard
to their influence on survival of metastatic melanoma patients.
Surprisingly, this analysis revealed that patients carrying B-RAF
mutations had an impaired survival, whereas patients with N-RAS
mutations were characterized by a favorable prognosis, each in
comparison with the wildtype gene status. Moreover, multivariate
data analysis showed that N-RAS but not B-RAF mutation status
was an independent prognostic factor.
The mechanisms how N-RAS mutations contribute to an
improved survival of melanoma is not yet fully understood.
However, it could be speculated to be related to the differences in
the downstream effectors between RAS and RAF. As mentioned
above, it has been presumed until recently, that the primary
function of RAS was simply to facilitate RAF activation. However,
the discovery of other proteins that are effectors of RAS function
suggested, that oncogenic activities of RAS are mediated by both
RAF-dependent and RAF-independent signalling. Notably, fur-
ther complexity arose with the identification of RAS effectors (e.g.
RASSF1-2 or NORE1) with putative tumor suppressor, rather
than oncogenic functions [18]. Our previous analysis of gene
expression profiles of melanoma cell lines with either mutations in
B-RAF or N-RAS revealed substantial differences including
expression of tumor suppressor genes and oncogenes [16]. In this
respect, it is important to note, that Demunter et al. described an
N-RAS mutation at codon 18 in melanoma tissues, that was
associated with a favorable disease outcome [19]. However, this
particular mutation was not detected in the tumor material
analyzed in our present study. Nevertheless, the association of
oncogenic mutations with a favorable prognosis is not without
a precedent. In bladder cancer, FGFR3 mutations have been
associated with a prolonged survival and tumors carrying these
mutations constitute a favorable disease category [20]. A
completely different explanation may rely on the different
immunogenicity of mutated B-RAF and N-RAS or the respective
induced effector molecules, as it has been recently suggested for
the seemingly paradoxical association of a bcl-2 over-expression
with an improved prognosis in cancer patients [21].
The negative impact of B-RAF mutations on survival was
slightly more apparent in the analysis of tissues than in the analysis
of cell lines. In contrast, N-RAS mutations were associated with
a favorable prognosis, though statistical significance was reached
only in results from cell lines. One of the possible reasons might be
that we did not succeed in establishing a cell line from every tissue
biopsy, resulting in an unintended selection bias, which might favor
the establishment of cell lines carrying N-RAS mutations. This is
supported by our observation that in five cases mutations in the N-
RAS gene were present in tumor cell lines but not in the
corresponding tissue samples. Another unbalanced parameter was
based on the inclusion of malignant effusions, from which only cell
lines but no corresponding tissues could be derived. This fact might
have created a bias between the patient populations from whom
tumor cell lines and/or tissues could be analysed, which is of
particular relevance because melanoma patients presenting
malignant effusions are known to show an extremely poor
prognosis. Our study population included seven cell lines derived
from malignant effusions, all of which were negative for N-RAS
mutations. This observation might explain the differences seen
between N-RAS mutated and wildtype cell lines towards prognosis.
Taken together, we demonstrate that the mutational status of B-
RAF and N-RAS are well preserved during short term in vitro
propagation, and, most importantly, that B-RAF and N-RAS
mutations differentially impact the outcome of melanoma patients.
These findings should be considered in conjunction with
therapeutic strategies under current investigation, using B-RAF
and N-RAS as molecular targets [22], e.g. considering the
observation that inhibitors of N-RAS like farnesyltransferase
inhibitors might not be effective in melanoma therapy [23].
Future clinical trials in this field should be accompanied by
a focused molecular workup of patient material in order to provide
further insights into the impact of mutational profiles on the
prognosis and therapy response of melanoma patients.
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